Roche Holding : Une publication S1 2020 difficile qui ne change pas les perspectives
>Le confinement a limité le recours aux soins - Roche nous a surpris négativement hier avec sa publication S1. Alors que le T1 n’avait essentiellement expérimenté que l’impact positif de COVID-19 (tests PCR et Actemra), la deuxième partie du semestre a bel et bien vu une diminution de l’activité (rappelons-le avec même -15% au mois de mai !). Les mesures de confinement ont clairement empêché les patients de voir leurs médecins, de se rendre à l’hôpital ou encore de fa...Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.